Piperidine derivatives useful as CCR5 antagonists

Details Piperidine derivatives useful as CCR5 antagonists Piperidine derivatives useful as CCR5 antagonists

2003-07-29

2008-10-28

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S333000

Reexamination Certificate

active

07442703

ABSTRACT:
The present invention provides a compound of the formulaor a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R9, R10, A and B are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.

REFERENCES:
patent: 5952349 (1999-09-01), Asberom et al.
patent: 2004/0142920 (2004-07-01), Albert et al.
patent: 0 151 824 (1985-08-01), None
patent: 0 855 999 (2001-10-01), None
patent: WO 97/24324 (1997-07-01), None
patent: WO 98/01425 (1998-01-01), None
patent: WO 01/30348 (2001-05-01), None
patent: WO 01/77101 (2001-10-01), None
patent: WO 02/081449 (2002-10-01), None
patent: WO02/081449 (2002-10-01), None
Janssens et al. “N-r-piperidinyl bicyclcic . . . ” Ca 104:50874 (1986).
Braga et al. “Making crystals from crystals . . . ” Chem. Commun. (2005) p. 3635-3645.
Anandan Palani et al., “Discovery of 4-[(Z)-(4-Bromophenyl)-(ethoxyimino)methyl]-1′-[(2,4—dimethyl-3-pyridinyl)carbonyl]-4′-methyl-1,4′-bipiperidine N-Oxide (SCH 351125): An Orally Bioavailable Human CCR5 Antagonist for the Treatment of HIV Infection”, Journal of Medicinal Chemistry, vol. 44, No. 21, Oct. 11, 2001, pp. 3339-3342.
Molla et al., “Human Serum Attenuates the Activity of Protease Inhibitors toward Wild-Type and Mutant Human Immunodeficiency Virus”, Virology (1998), p. 255-262, vol. 250.
Peterson et al., “Influence of Protein Bindingon Therapeutic Efficacy of Cefoperazone”, Antimicrobial Agents and Chemotherapy (Apr. 1989), p. 566-568, vol. 33, No. 4.
Peterson et al., “Effect of Protein Binding on Simulated Intravascular and Extravascular Kinetics of Cefotaxime in an In Vitro Model”, Antimicrobial Agents and Chemotherapy (Jan. 1984), p. 58-61, vol. 25, No. 1.
Bilello et al., “Human Serum α1Acid Glycoprotein Reduces Uptake, Intracellular Concentration, and Antiviral Activity of A-80987, an Inhibitor or the Human Immunodeficiency Virus Type 1 Protease”, Antimicrobial Agents and Chemotherapy, (Jun. 1996), p. 1491-1497. vol. 40, No. 6, American Society for Microbiology.
Bilello et al., “Reduction of the in Vitro Activity of A77003, an Inhibitor of Human Immunodeficiency Virus Protease, by Human Serum α1Acid Glycoprotein”, The Journal of Infectious Diseases, (1995), p. 546-51, vol. 171.
Bryant et al., “SC-52151, a Novel Inhibitor of the Human Immunodeficiency Virus Protease”, Antimicrobial Agents and Chemotherapy, (Oct. 1995), p. 2229-2234, vol. 39, No. 10, American Society for Microbiology.
Fischl et al., “Phase I/II Study of the Toxicity, Pharmacokinetics, and Activity of the HIV Protease Inhibitor SC-52151”, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, (1997), p. 28-34, vol. 15, No. 1, Lippincott-Raven Publishers, Philadelphia.
Goldberg et al., “DuP 532, an angiotensin II receptor antagonist: First administration and Comparison with Iosartan”, Clinical Pharmacology & Therapeutics, (Jan. 1997), p. 59-69, vol. 61, No. 1.
Maillard et al., “Does protein binding modulate the effect of angiotensin II receptor antagonists?”, Journal of the Renin-Angiotensin-Aldosterone System, (Mar. 2001), p. S54-S58, vol. 2, Supplement 1.
Trainor, “The importance of plasma protein binding in drug discovery”, Expert Opin. Drug Discov., (2007), p. 51-64, vol. 2, No. 1.

Affiliated with

Also associated with

Rating

Piperidine derivatives useful as CCR5 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Piperidine derivatives useful as CCR5 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidine derivatives useful as CCR5 antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4016586